Compare CVS Health Corp (CVS) vs Elastic NV (ESTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Elastic NV — how do they compare? CVS Health Corp trades at $86.27 (market cap $112.29B), while Elastic NV trades at $96.62 (market cap $10.00B). The key difference: CVS Health Corp is far larger — about 11.2× Elastic NV's market cap, and CVS Health Corp pays a 3.03% dividend while Elastic NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Elastic NV for 10 Days on average.
| CVS | ESTC | |
|---|---|---|
Market Cap | $112.29B | $10.00B |
Volume | 7,763,676 | 1,610,337 |
Sector | Health | Technology |
52-Week High | $110.60 | $99.91 |
52-Week Low | $70.08 | $43.30 |
Typical Hold Time | 83 Days | 10 Days |
Enterprise Value | $174.64B | $9.14B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
Elastic (ESTC) trades at $96.44, up 3.59% today, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches in AI and observability platforms highlight innovation, while profitability metrics show improvement into 2026. The current price sits near resistance at $97, with RSI indicating potential overbought conditions short-term.
Outlook remains positive given earnings momentum and product expansion, but risks include high valuation multiples and insider selling. The consensus price target of $79.50 suggests caution, though bullish sentiment prevails with 65% buy ratings. Investors should weigh growth potential against execution risks in a competitive software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
